Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- CMS Relocates ESRD Survey Procedures and Interpretive Guidance Posted 06-17-2026
- CMS announced new 5-year contracts for ESRD Networks, which started May 1 Posted 06-17-2026
- Simon Davies Discusses the Role of PD in Expanding Dialysis Acess Posted 05-15-2026
- Less Home Dialysis and Transplant in Pediatric Patients Transitioning to Adult Clinics Posted 05-15-2026

